GlassScriptPhysician profile
John Anthony Haefele
NPI 1467475186
$1,044.23
in general payments reported to CMS, 2019-2025
12 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.50 · 2020: $72.38 · 2021: $276 · 2022: $200 · 2023: $215 · 2024: $84.33 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $147.52 | 2020-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $147.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $144.77 | 2021-2024 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $139.82 | 2020-2023 | Otezla, Repatha |
| Abbvie INC. | $131.12 | 2021-2024 | |
| Lilly USA, LLC | $98.97 | 2021-2023 | Trulicity, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.81 | 2025 | Caplyta |
| Astellas Pharma US INC | $49.62 | 2019-2020 | |
| Mylan Specialty L.P. | $38.91 | 2021-2023 | Yupelri |
| Amarin Pharma, INC. | $27.23 | 2020-2021 | |
| Viatris Specialty LLC | $14.47 | 2025 | Yupelri |
| Pfizer INC. | $12.98 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Haefele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.